What are the National Comprehensive Cancer Network (NCCN) guidelines for supportive care in the treatment of acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The NCCN guidelines recommend that all patients receive supportive care that includes the following [25] :

  • Use of leukodepleted, irradiated blood products

  • Tumor lysis prophylaxis — Not all AML patients are at high risk for tumor lysis syndrome (TLS). Independent risk factors for TLS are pretreatment serum lactate dehydrogenase (LDH) levels above laboratory normal values, creatinine > 1.4 mg/dL, uric acid > 7.5 mg/dL and white blood cell (WBC) counts > 25 x 109/L.

  • Growth factors for post-remission therapy may be considered but may impact interpretation of the bone marrow evaluation

  • Use and choice of antibiotics for prophylaxis should be based on the prevailing organisms and their drug resistance patterns

  • Patients receiving high-dose cytarabine require neurologic assessment before each dose. Cytarabine should be stopped in those who develop cerebellar toxicity.  

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!